Abstract
Purpose Recently introduced Large Language Models (LLMs) such as ChatGPT have already shown promising results in natural language processing in healthcare. The aim of this study is to systematically review the literature on the applications of LLMs in breast cancer diagnosis and care.
Methods A literature search was conducted using MEDLINE, focusing on studies published up to October 22nd, 2023, using the following terms: “large language models”, “LLM”, “GPT”, “ChatGPT”, “OpenAI”, and “breast”.
Results Five studies met our inclusion criteria. All studies were published in 2023, focusing on ChatGPT-3.5 or GPT-4 by OpenAI. Applications included information extraction from clinical notes, question-answering based on guidelines, and patients’ management recommendations. The rate of correct answers varied from 64-98%, with the highest accuracy (88-98%) observed in information extraction and question-answering tasks. Notably, most studies utilized real patient data rather than data sourced from the internet. Limitations included inconsistent accuracy, prompt sensitivity, and overlooked clinical details, highlighting areas for cautious LLM integration into clinical practice.
Conclusion LLMs demonstrate promise in text analysis tasks related to breast cancer care, including information extraction and guideline-based question-answering. However, variations in accuracy and the occurrence of erroneous outputs necessitate validation and oversight. Future works should focus on improving reliability of LLMs within clinical workflow.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos